NCT03028480Completed
Long Term Special Drug Use Investigation of Mepolizumab
Nucala® Subcutaneous Injection Special Drug Use Investigation (Long-Term)
Source: ClinicalTrials.gov · Last updated 20 Sept 2024
Brief summary (registry, in English)
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC). In this study the information regarding the safety and effectiveness of long term use of NUCALA after subcutaneous injection will be collected from Asthma subjects in daily clinical practice. The observation period per subject will be 52 weeks from the initiation of NUCALA treatment with follow-up investigation for 2 years after the observation period. NUCALA is a registered trademark of the GlaxoSmithKline \[GSK\] group of companies
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1061 (actual)
- First submitted
- 6 Jan 2017
- Start date
- 11 Jan 2017
- Primary completion date
- 22 Nov 2023
- Lead sponsor
- GlaxoSmithKline
- Diseases
- Asthma
- NCT number
- NCT03028480
What you commit to
- Study type: Observational
- Participants enrolled: 1061
- From 11 Jan 2017 to the primary completion date, 22 Nov 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria
Who the study is looking for
- Subjects receiving NUCALA for the first time for treatment of bronchial asthma (a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications)
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.